Literature DB >> 11959606

In vitro activities of free and lipid formulations of amphotericin B and nystatin against clinical isolates of Coccidioides immitis at various saprobic stages.

Gloria M González1, Rolando Tijerina, Deanna A Sutton, John R Graybill, Michael G Rinaldi.   

Abstract

We investigated the susceptibilities of hyphal, mixed hyphal, ungerminated arthroconidial, and germinated arthroconidial populations of Coccidioides immitis to lipid formulations of amphotericin B and nystatin and their conventional preparations, utilizing the National Committee for Clinical Laboratory Standards M38-P broth macrodilution method. The differences in effects of the three different growth stages of the saprobic phase of C. immitis on the MIC/minimum lethal concentration (MLC) ratio were not statistically significant for any of the antifungal agents tested. These results suggest that either inocula could be used for in vitro susceptibility studies with C. immitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959606      PMCID: PMC127125          DOI: 10.1128/AAC.46.5.1583-1585.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi.

Authors:  J Guarro; C Llop; C Aguilar; I Pujol
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

2.  Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B fgainst Fusarium.

Authors:  I Pujol; J Guarro; J Sala; M D Riba
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 3.  Lipid formulations of amphotericin B: recent progress and future directions.

Authors:  J W Hiemenz; T J Walsh
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

4.  Standardization of a hyphal inoculum of aspergilli for amphotericin B susceptibility testing.

Authors:  V Bezjak
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

5.  Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents.

Authors:  E K Manavathu; J Cutright; P H Chandrasekar
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

6.  Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method.

Authors:  A Gehrt; J Peter; P A Pizzo; T J Walsh
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

7.  Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections.

Authors:  R T Mehta; R L Hopfer; T McQueen; R L Juliano; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

  7 in total
  4 in total

1.  Comparison of in vitro antifungal susceptibilities of conidia and hyphae of dermatophytes with thick-wall macroconidia.

Authors:  Belkys Fernández-Torres; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.

Authors:  Ritam Sidhu; David B Lash; Arash Heidari; Piruthiviraj Natarajan; Royce H Johnson
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  In Vitro Evaluation of Radiolabeled Amphotericin B for Molecular Imaging of Mold Infections.

Authors:  Sebastian Wurster; Samuel Samnick; Lukas Page; Andrew J Ullmann; Fabian Schadt
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 4.  Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.

Authors:  Brenda Kischkel; Suélen A Rossi; Samuel R Santos; Joshua D Nosanchuk; Luiz R Travassos; Carlos P Taborda
Journal:  Front Cell Infect Microbiol       Date:  2020-09-03       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.